Sharps Technology sets $20 million public offering price

Published 28/01/2025, 15:06
Sharps Technology sets $20 million public offering price

NEW YORK - Sharps Technology, Inc. (NASDAQ: STSS), a medical device and pharmaceutical packaging company known for its smart-safety syringe products, has announced the pricing of its public offering aimed at raising approximately $20 million. According to InvestingPro data, the company, currently valued at just $2.99 million, has been facing significant cash burn challenges and trades near its 52-week low of $1.38. Analysis suggests the stock may be undervalued at current levels. The offering, underwritten on a firm commitment basis, includes 14,285,714 units, each comprising a share of common stock or a pre-funded warrant, and accompanying warrants to purchase additional shares.

The public offering price is set at $1.40 per common unit, with pre-funded units priced at $1.3999, reflecting the common unit price minus the pre-funded warrant exercise price of $0.0001. These pre-funded warrants are immediately exercisable and will remain so until fully exercised. With the stock showing a -79.82% return over the past year and significant volatility, InvestingPro subscribers can access 13 additional key insights about STSS's financial health and market position.

Each unit also contains a Series A and Series B Registered Common Warrant, both with an exercise price of $1.75 per share. The Series A Warrants are exercisable immediately and will expire five years after stockholder approval, while the Series B Warrants can be exercised immediately with an expiration date two and a half years post-approval. Adjustments to the number of securities issued under these warrants are detailed in the upcoming Form 8-K report.

To address potential over-allotments, Sharps Technology has granted Aegis Capital Corp., the sole book-running manager for the offering, a 45-day option to purchase up to an additional 15% of the shares and warrants sold.

The proceeds from this offering, which is expected to close around January 29, 2025, subject to customary closing conditions, are intended for general corporate purposes and working capital. This capital raise comes at a crucial time, as InvestingPro analysis shows the company reported negative EBITDA of -$7.89 million in the last twelve months, highlighting the importance of strengthening its financial position.

Investors can look forward to a final prospectus supplement and accompanying prospectus detailing the offering terms, which will be filed with the U.S. Securities and Exchange Commission and available on their website.

This press release is based on a press release statement and does not constitute an offer to sell or a solicitation of an offer to buy in any state or jurisdiction where such an offer would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

In other recent news, Sharps Technology Inc. reported significant financial activities and governance decisions. The company secured a $484,438 stock sale agreement with institutional investors, selling 248,430 shares at $1.95 per share. Additionally, Sharps Technology closed a $3.5 million secured bridge loan financing agreement, with Aegis Capital Corp. acting as the exclusive placement agent.

The company's annual shareholder meeting led to the election of six directors to the Board and the ratification of PKF O’Connor Davies LLP as the accounting firm for the fiscal year ending December 31, 2024. Shareholders also approved a new equity incentive plan and an increase in authorized common stock shares from 100 million to 500 million.

Further, Sharps Technology amended its bylaws to require a minimum of one-third of stockholders to be present for the transaction of any business at stockholder meetings. The Board of Directors has been granted the authority to execute a reverse stock split of up to 1-for-8 within a year. These are recent developments that could potentially impact the company's future direction.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.